218 related articles for article (PubMed ID: 18767946)
1. Strategies used for MUC1 immunotherapy: human clinical studies.
Tang CK; Katsara M; Apostolopoulos V
Expert Rev Vaccines; 2008 Sep; 7(7):963-75. PubMed ID: 18767946
[TBL] [Abstract][Full Text] [Related]
2. Strategies used for MUC1 immunotherapy: preclinical studies.
Tang CK; Apostolopoulos V
Expert Rev Vaccines; 2008 Sep; 7(7):951-62. PubMed ID: 18767945
[TBL] [Abstract][Full Text] [Related]
3. MUC1 as a target antigen for cancer immunotherapy.
Acres B; Limacher JM
Expert Rev Vaccines; 2005 Aug; 4(4):493-502. PubMed ID: 16117706
[TBL] [Abstract][Full Text] [Related]
4. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
Yuan S; Shi C; Liu L; Han W
Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
[TBL] [Abstract][Full Text] [Related]
5. Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses.
Tang CK; Sheng KC; Pouniotis D; Esparon S; Son HY; Kim CW; Pietersz GA; Apostolopoulos V
Vaccine; 2008 Jul; 26(31):3827-34. PubMed ID: 18550230
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
Acres B
J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
[TBL] [Abstract][Full Text] [Related]
7. Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2.
He J; Shen D; O'Donnell MA; Chang HR
Int J Oncol; 2002 Jun; 20(6):1305-11. PubMed ID: 12012014
[TBL] [Abstract][Full Text] [Related]
8. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
[TBL] [Abstract][Full Text] [Related]
9. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
[TBL] [Abstract][Full Text] [Related]
10. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.
Karanikas V; Hwang LA; Pearson J; Ong CS; Apostolopoulos V; Vaughan H; Xing PX; Jamieson G; Pietersz G; Tait B; Broadbent R; Thynne G; McKenzie IF
J Clin Invest; 1997 Dec; 100(11):2783-92. PubMed ID: 9389743
[TBL] [Abstract][Full Text] [Related]
11. MUC1 immunotherapy.
Beatson RE; Taylor-Papadimitriou J; Burchell JM
Immunotherapy; 2010 May; 2(3):305-27. PubMed ID: 20635898
[TBL] [Abstract][Full Text] [Related]
12. Design of a MUC1-based cancer vaccine.
Hanisch FG
Biochem Soc Trans; 2005 Aug; 33(Pt 4):705-8. PubMed ID: 16042579
[TBL] [Abstract][Full Text] [Related]
13. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
Rochlitz C; Figlin R; Squiban P; Salzberg M; Pless M; Herrmann R; Tartour E; Zhao Y; Bizouarne N; Baudin M; Acres B
J Gene Med; 2003 Aug; 5(8):690-9. PubMed ID: 12898638
[TBL] [Abstract][Full Text] [Related]
14. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical safety evaluation of heat shock protein 65-MUC1 peptide fusion protein.
Huo Y; Li B; Zhang Y; Wang S; Bao M; Gao X; Li D; Wang L; Yu Y; Wang J
Regul Toxicol Pharmacol; 2007 Oct; 49(1):63-74. PubMed ID: 17600604
[TBL] [Abstract][Full Text] [Related]
16. MUC1 immunobiology: from discovery to clinical applications.
Vlad AM; Kettel JC; Alajez NM; Carlos CA; Finn OJ
Adv Immunol; 2004; 82():249-93. PubMed ID: 14975259
[No Abstract] [Full Text] [Related]
17. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
[TBL] [Abstract][Full Text] [Related]
18. [Adoptive immunotherapy for pancreatic cancer, using MUC1 specific CTL].
Masaki Y; Oka M
Gan To Kagaku Ryoho; 1996 Oct; 23(12):1679-80. PubMed ID: 8886044
[TBL] [Abstract][Full Text] [Related]
19. [MUC1, a therapeutic target in oncology].
Limacher JM; Acres B
Bull Cancer; 2007 Mar; 94(3):253-7. PubMed ID: 17371767
[TBL] [Abstract][Full Text] [Related]
20. MUC1 immunotherapy is here to stay.
Kimura T; Finn OJ
Expert Opin Biol Ther; 2013 Jan; 13(1):35-49. PubMed ID: 22998452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
